Immunotherapy Extends Cancer Patient Life by 40% | Research News
- A new clinical trial indicates that CAR T-cell therapy, a form of immunotherapy that uses genetically modified cells, can extend the lives of cancer patients by 40%.
Groundbreaking research reveals CAR T-cell therapy dramatically extends cancer patient survival. A clinical trial shows a 40% increase in life expectancy for advanced gastric cancer patients, representing a significant leap forward in cancer treatment. This innovative immunotherapy approach involves modifying a patient’s own T-cells to target and eliminate cancerous tumors effectively. Witnessing these remarkable outcomes at the American Society of Clinical Oncology (ASCO) meeting underscores the potential of CAR T-cell therapy as a powerful tool in the fight against cancer, providing new hope and treatment avenues. News Directory 3 delivers this crucial update and many more like it. Discover what’s next for this promising therapy.
CAR T-Cell Therapy Shows Promise in Extending Cancer Survival
Updated May 31, 2025
A new clinical trial indicates that CAR T-cell therapy, a form of immunotherapy that uses genetically modified cells, can extend the lives of cancer patients by 40%. The trial focused on patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer. This advancement in cancer treatment offers new hope for those with limited options.
The CAR T-cell therapy process involves extracting a patient’s T-cells, modifying